Wilmington, DE – May 20, 2008 – A new 12-week study2examined safety and efficacy measures of the maintenance combination asthma therapy, SYMBICORT® (budesonide ...

DENVER--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced results from a long-term study comparing SYMBICORT ® (budesonide/ formoterol fumarate dihydrate) Inhalation Aerosol 160/4.5 mcg with ...

August 22, 2008 — A budesonide/formoterol (Symbicort, AstraZeneca) pressurized metered-dose inhaler (pMDI) showed safety and better asthma control versus budesonide alone, according to the results of ...

The US Food and Drug Administration has approved AstraZeneca's Symbicort inhalation aerosol (80/4.5 mcg) for children aged 6 to 12 years with asthma that is not well controlled with an inhaled ...

Wilmington, DE – June 4, 2008 – AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...

Symbicort contains the active medications budesonide and formoterol. Budesonide belongs to a drug class called corticosteroids. Formoterol belongs to a drug class called long-acting beta2 agonists.

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced the publication of data demonstrating that SYMBICORT Inhalation Aerosol 320/9 µg twice daily had a safety profile similar to ...

The pediatric approval was based on the results of the Phase 3 CHASE (ChildHood Asthma Safety and Efficacy) 3 trial. The Food and Drug Administration (FDA) has approved Symbicort (budesonide and ...

The dosage for Symbicort may vary based on age and diagnosis, but it’s typically two inhalations twice daily. For children ages 6 to 11, the maximum strength is 80/4.5 mcg. For ages 12 and older, a ...

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) SYMBICORT is a combination asthma medication that contains both an inhaled corticosteroid (ICS ...